Cross-Sector entity
Every one of those 1 sits in a single category, pharma. Corcept Therapeutics Incorporated is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 10 original sources on average. We currently track 1 Cross-Sector story that mention Korlym, all published on February 24, 2026.
1 verified story tracked
Last mentioned: Feb 24, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Corcept Therapeutics Incorporated is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 10 original sources on average. We currently track 1 Cross-Sector story that mention Korlym, all published on February 24, 2026.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Korlym. Shared-story counts are live from our verified record — not editorial picks.
Lawsuit Announced
Rosen Law Firm announces the filing of the securities fraud class action.
Appellate Loss
Teva Pharmaceuticals wins a key appeals court decision against Corcept's Korlym patents.
Class Period Ends
Conclusion of the period following corrective disclosures or market events.
Class Period Begins
Start of the period during which alleged misleading statements were made.
Rosen Law Firm has filed a class action lawsuit against Corcept Therapeutics (NASDAQ: CORT), alleging securities fraud during a period of intense patent litigation over its flagship drug, Korlym. The lawsuit covers investors who purchased shares between October 2024 and December 2025, following significant volatility linked to generic competition threats.
